1162 related articles for article (PubMed ID: 1928075)
1. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
Moran LJ; Carey P; Johnson CA
Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
5. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure--an interim report. The National Cooperative rHu Erythropoietin Study Group.
Levin NW; Lazarus JM; Nissenson AR
Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):3-12. PubMed ID: 8352269
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
7. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
8. Review of patients' responses to epoetin alfa therapy.
Krantz SB
Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
[TBL] [Abstract][Full Text] [Related]
9. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
[TBL] [Abstract][Full Text] [Related]
11. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
Johnson CA; Rosowski E; Zimmerman SW
Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
[TBL] [Abstract][Full Text] [Related]
12. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
Glaspy J
Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
[TBL] [Abstract][Full Text] [Related]
13. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
14. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
15. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
[TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
19. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
20. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
